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Abstract
Background: Cough is a common and distressing symptom in lung cancer patients. The clinical management of
cough in lung cancer patients is suboptimal with limited high quality research evidence available. The aim of the
present paper is to present a clinical guideline developed in the UK through scrutiny of the literature and expert
opinion, in order to aid decision making in clinicians and highlight good practice.
Methods: Two systematic reviews, one focusing on the management of cough in respiratory illness and one
Cochrane review specifically on cancer, were conducted. Also, data from reviews, phase II trials and case studies
were synthesized. A panel of experts in the field was also convened in an expert consensus meeting to make
sense of the data and make clinical propositions.
Results: A pyramid of cough management was developed, starting with the treatment of reversible causes of
cough/specific pathology. Initial cough management should focus on peripherally acting and intermittent
treatment; more resistant symptoms require the addition of (or replacement by) centrally acting and continuous
treatment. The pyramid for the symptomatic management starts from the simpler and most practical regimens
(demulcents, simple linctus) to weak opioids to morphine and methadone before considering less well-researched
and experimental approaches.
Conclusion: The clinical guidelines presented aim to provide a sensible clinical approach to the management of
cough in lung cancer. High quality research in this field is urgently required to provide more evidence-based
recommendations.
1. Introduction
Cough is a common symptom in about 23-37% of gen-
eral cancer patients and 47-86% of lung cancer patients
[1]. The first author’s data on 100 cancer patients
assessed using the Memorial Symptom Assessment
Scale from the beginning of cancer treatment to 3, 6
and 12 months showed a prevalence of 42.9%, 39.2%,
35.1% and 36.1% respectively, similarly to the experience
of breathlessness, although less distressing than breath-
lessness [2]; these numbers almost doubled in the lung
cancer subgroup analysis. Despite such high prevalence,
the management of cough remains suboptimal, with
little high quality evidence to guide practice. Much of
the current practice on the symptomatic management of
cough in lung cancer is experiential and primarily is
geared around the use of oral opioids. Current guide-
lines on the management of cough are often broad and
non-specific (suggesting difficulty in making any specific
recommendations) and either focus on non-cancer
respiratory illnesses with different pathophysiology from
cancer-related cough, or provide broad reviews of gener-
ally poor quality studies [3-7]. Professional societies that
have developed guidelines (non-cancer) include the
American College of Chest Physicians (ACCP) [3,8], the
European Respiratory Society (ERS) [9] and the British
Thoracic Society (BTS) [7].
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With currently available information, clinicians have dif-
ficulty in making appropriate treatment choices, often
treating patients on a trial-and-error basis. This has
been highlighted through discussions with many clini-
cians. Our own work with lung cancer patient interviews
over time [10] has shown the distressing nature of
cough and its significant impact on patients’ quality of
life as well as the difficulty in obtaining relief from
offered treatments. Our consultation with patient
research forums has also highlighted the management of
cough as an unmet need in lung cancer. For these rea-
sons, the development of clinical guidelines for the man-
agement of cough in lung cancer was deemed necessary
and timely.
2. Process of guidelines development
2.1. Formation of the Task Group
The Task Group was led by the Cancer Experiences
Research Collaborative (CECo) with invited experts
from the Association for Palliative Medicine (APM).
CECo (see http://www.ceco.org.uk) is a collaborative of
five UK universities and their clinical partners, funded
in 2005 by the National Cancer Research Institute to
develop critical mass, capacity and high quality research
in supportive and palliative care. Besides its research
objectives, the Collaborative also has a remit to have the
maximum positive impact on policy and practice. The
APM (see http://www.palliative-medicine.org) is a pro-
fessional society aiming to provide a national and regio-
nal network for palliative medicine doctors with a
strong focus on developing and implementing educa-
tional material, and has strong links with the European
Association for Palliative Care.
The Task Group consisted of experts that repre-
sented palliative medicine, medical/clinical oncology
with focus in lung cancer, respiratory medicine, nur-
sing, pharmacy, and supportive care. Experts had clini-
cal, academic and research roles and three members of
the group were also running cough clinics in the UK.
Members of the group have also significant research
publications in relation to cough, considered key
experts in this (limited) field. The group met twice,
once to agree on the methodology to be used and
review the available evidence and once to make sense
of this data and develop recommendations.
2.2. Evidence searching and selection
A literature review preceded the meetings over the pre-
vious year, with two systematic reviews being underta-
ken, one with a focus on cough and respiratory illnesses
(other than cancer) [11] and a second Cochrane review
with a focus specifically in cancer [12]. Other publica-
tions, including reviews, case study reports and phase II
trials that were not part of the systematic reviews were
also retrieved and summarized. The group members
reviewed the evidence and made recommendations that
reflected the evidence found combined with clinical
experience in an attempt to provide a sensible approach
to the clinician and guide practice in a field with mini-
mal evidence.
2.3. Clinical consultation of the guidelines
An assessment of the appropriateness, usability and
clarity of the guidelines was carried out by international
experts (N = 15), including 9 consultants in palliative
medicine, 4 in medical oncology and 2 specialist pallia-
tive care nurses (independent prescribers). This was
done through clinicians reading the report and recom-
mendations, and completing a feedback form. A number
of items structured in a Likert-type format of 1 =
strongly disagree to 5 = strongly agree were included.
The areas explored were: the rationale and need for the
guidelines (original score = 4.6); the need for the devel-
opment of the guidelines (= 4.8); completeness of litera-
ture search (= 4.3); the description of evidence (= 4.6);
the methods used to summarise and interpret the evi-
dence (= 4.1); interpretation of the evidence presented
(= 4); clarity of the recommendations (= 3.7); agreement
with the recommendations made (= 4.1), and feeling
comfortable having these guidelines applied in their hos-
pital (= 4). The likelihood of using these guidelines in
the reviewers’ own practice was explored with a single-
item scale ranging from 1 = ‘not at all likely to use’ to
10 = ‘very likely to use’, achieving a score of 8.1. After
the feedback, the guidelines were modified primarily in
relation to the dosages in some drugs, and the clarity
and levels of drugs proposed in the cough pyramid (Fig-
ure 1).
3. Review of the evidence
3.1. Pathophysiology and causes of cough
In healthy individuals coughing serves to protect the
airway from chemical irritants and foreign bodies.
These stimuli provoke coughing by stimulation of
afferent C fibres (chemoreceptors) and Aδ fibres
(mechanoreceptors) in the airways, carried by the
vagus nerve. In disease states, excessive coughing can
occur by excessive noxious stimulation of these affer-
e n tf i b r e sa n d / o ra sar e s u l tof sensitization of neurons
involved in the cough reflex. In patients with lung can-
cer, for example, tumour tissue in the central airways
may cause mechanoreceptor stimulation directly or
indirectly via obstruction and sputum accumulation.
The inflammatory mediators associated with infection
distal to such an obstruction or mediators released by
tumour tissue may further induce coughing by sensitiz-
ing peripheral nerves.
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result of non-cancer related underlying pathology or
cancer itself. The cancer-related causes of cough can
include a direct effect of the tumour mass (ie. obstruc-
tion), pleural or pericardial effusion, atelectasis, infec-
tions, oesophagorespiratory fistulas, lympangitic
carcinomatosis, superior vena cava syndrome and treat-
ment-induced cough as a result of radiotherapy or more
rarely chemotherapy [5].
3.2. Quality and relevance of identified clinical studies
Positive and negative trials from our systematic review
of cough management in respiratory and non-respira-
tory diseases are summarized in Table 1, summarising
data from 75 trials. The key points from this review
were that several pharmacological approaches and one
non-pharmacological (speech pathology training) had
the potential of improving the experience of cough [11].
However, as only 20/75 trials had cough as a primary
outcome being primarily trials focusing on a respiratory
pathology, the reliability of the outcome measurement
was debatable in the vast majority of trials, and a signifi-
cant proportion of trials had methodological and quality
problems.
Research into cancer-related cough was even more
disappointing, and our Cochrane systematic review [12]
identified only 17 studies meeting the inclusion criteria.
Almost half were studies investigating the effects of bra-
chytherapy and nine trials assessed the effectiveness of a
number of drugs (Table 1). All brachytherapy trials were
of very low quality (Jadad score of ‘0’)a n do f t e nt h e r e
was lack of clarity in the papers about key methodologi-
cal processes. Nevertheless, these studies suggest that
treatment with brachytherapy may be appropriate in
selected populations of lung cancer patients. The phar-
macological studies were mostly of low quality using
small samples, half had mixed samples of non-cancer
and cancer patients and several were over 30 years old.
We also assessed other trials that were not included in
the above reviews, phase II trials and experimental case
Figure 1 Treatment pyramid for the management of cough in patients with lung cancer.
1(e.g. Benylin tickly coughs; Lemsip cough dry).
2
(e.g. Actifed dry coughs; Meltus dry coughs; Benylin cough & congestion; Benylin dry coughs; Day & Night Nurse-also includes pholcodine-;
Night Nurse; Vicks cold & flu care medinite complete syrup; Robitussin for dry coughs oral or soft pastilles). Dextromethorphan is in variable
concentrations in each of these preparations, containing 6.5-11.5 mg/ml. *Not available in the UK and some other countries. #Not
recommended, but to consider if everything else has failed.
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Page 3 of 8Table 1 Summary of evidence
Disease group & number of trials Interventions with positive data Interventions
with negative
data
Overview of findings
from systematic
review in respiratory
diseases [11]*
1. Asthma (cough often secondary
outcome)
N = 23 trials, 1508 subjects
Steroids (particularly Beclomethasone-4 trials-and Budesonide-1
trial)
Disodium Cromoglycate-1 trialLodoxadine-1 trial
Nedocromil sodium-2 trials
Leukotriene receptor antagonists-2 trials
Th2 cytokine inhibitor-1 trial
Theophylline-1
trial
Nedocromil
sodium-2 trials
2. Chronic Bronchitis
N = 8 trials, 731 subjects
Epinastine-1 trial
Ipratropium bromide-1 trial
Theophylline-1 trial
Iodinised glycerol-2 trials
Low dose N-
acetylcysteine-1
trial
Budenoside-1
trial
3. COPD
N = 8 trials, 8013 subjects
Fenspiridine-1 trial
Fluticasone-1 trial
Formoterol-1 trial
Neltenexine-3 trials
Helicidine-1 trial
Oxtriphylline-1 trial
High dose N-acetylcysteine-1 trial
Salbutamol/Iprapropium bromide-1 trial
Iprapropium bromide-1 trial
Budenoside-1
trial
Codeine-1 trial
Nesosteine-1
trial
Oxitropium
bromide-1 trial
4. Reflux disease
N = 5 trials, 258 subjects
Lansoprazole-1 trial
Omeprazole-2 trials
Esoprazole-1
trial
Omeprazole-1
trial
5. Idiopathic cough
N = 2 trials
Morphine-1 trial
Speech pathology training-1 trial
6. Other respiratory illnesses Codeine-2 trials
Benzonatate being equivalent to Codeine-1 trial
Moguiesteine being equivalent to Dextromethophran-1 trial
Neltenexine-2 trials
Sinecod linctus (butamirate) with a similar effect to that of small
dose of Codeine-1 trial
Overview of findings
from Cochrane
systematic review in
cancer [12]**
Lung cancer patients, N = 7 trials Brachytherapy in addition to EBRT resulted in higher
improvements in cough at doses of 15 Gy in 3 fractions; 14-16 Gy
in 2 fractions or 10 Gy in a single fraction
Lung cancer patients, N = 1 Photodynamic therapy (PDT) showing similar results to laser
therapy; its role as main treatment option questionable.
Pharmacological treatments, N = 9
(4 with mixed sample of patients with
respiratory illnesses including cancer.
Results extrapolated for cancer patients
only)
Codeine 30 mg + Phenyltoloxamine 10 mg bd-1 trial
Dihydrocodeine-1 trial
Hydropropizine (= Levodropropizine)-1 trial
Levodropropizine equivalent to Dihydrocodeine-1 trial
A Morphine derivative equivalent to Codeine in capsules (unclear
dose)
Sodium Cromoglycate 40 mg (2 puffs)
Butamirate linctus (overall no effect, but effective in cancer
subsample)
Case studies and
reviews
Cancer patients, often with advanced
disease
Morphine, Methadone, Pholcodine, Quaifenesin, Hydromorphone
(due to their antitussive activity) [review] [15]
Benzonatate for opioid-resistant cough [16]
Nebulized Morphine [17]
Nebulized Lidocaine [18]
Hydrocodone (phase II trial) 10 mg/d in divided doses [37]
Experimental studies
or studies in non-
cancer patients
GABAB agonists (such as Baclofen) [7]
Dextromethorphan 10-20 mg/4-6 hrs better than Codeine 20 mg
[13]
Moguestine 100 mg tid equivalent to Codeine 15-30 mg (non-
cancer patients) [14]
Nebulised Lidocaine [19,20,38]
Levocloperastine (novel antitussive) [21]
Paroxetine (in concomitant pruritus and cough) [22]
Amitryptiline, Gabapentin, Carbamazepine (in chronic cough) [23]
Thalidomide [24]
*Most of the therapeutic options here are not relevant to lung cancer-related cough, unless a relevant respiratory pathology is also present
**Most studies received a ‘0’ Jadad score representing studies with very low methodological quality.
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patients with chronic stable cough was included, receiv-
ing Dextromethorphan or Codeine (20 mg) [13]. Results
showed that Dextromethorphan reduced the intensity of
cough more than Codeine did (p < 0.0008) and was con-
sidered the better antitussive by the majority of patients.
In another randomized trial in 119 patients with various
respiratory illnesses and cough, Moguisteine 100 mg tid
was shown to be equally effective as Codeine [14].
Homsi et al [15] assessed the effects of Hydrocodone in
25 patients (20 completed the study) in a phase II trial.
Results suggested that Hydrocodone at a starting dose
of 10 mg/day in divided doses relieved cough in 70% of
the sample, although dose titrations were necessary.
Doona & Walsh [16] reported three cases who achieved
symptomatic relief in opioid-resistant cough using Ben-
zonatate, while Stein & Min [17] reported a single case
of a patient with metastatic cancer who was benefited
from the use of Nebulised Morphine for paroxysmal
cough and dyspnoea. The positive effect of Nebulised
Lidocaine was shown in a case study of a palliative care
patient [18] as well as case studies in patients with
respiratory diseases [19,20]. Aliprandi et al [21] reviewed
trials using a novel antitussive, Levocloperastine, sug-
gesting this has an improved efficacy and side effect
profile compared to other antitussives. The potential
role of Paroxetine, Baclofen, Amitryptiline, Gabapentin,
Thalidomide and Carbamazepine have also been sug-
gested through experimental work or in reviews
[7,22-24].
There are, however, some issues with some proposi-
tions in the literature, particularly in relation to the
effects of opioids. For example Homsi et al [15] men-
tioned a rank order of antitussive effects of opioids: The
preferred drug being Methadone (linctus), then Hydro-
morphone, then Morphine, then Codeine, then Oxyco-
done, in that order, citing Eddy et al [25] as source
document. However, the summary evidence following
each opioid in this 1957 monograph does not compare
antitussive effects against a standard nor against equi-
analgesic doses, and so does not support this ranking.
Also, Hydromorphone is said to be four times as potent
an antitussive as morphine but this is based on a study
that showed comparable effects in tuberculosis-related
cough between 10 mg Morphine and 2.5 mg Hydromor-
phone. Based on equi-analgesic dose conversions, no
opioid appears to be superior to another. Homsi et al
[15] state that Oxycodone is less potent than Morphine
as an antitussive (citing ref .25) but in fact the mono-
graph [25] states that they are equally effective. Further-
more, there may be a strong placebo effect with many
of the medications presented above (including weak
opioids), and whereas a placebo effect is clinically useful,
it needs to be considered in the interpretation of the
data available.
4. Recommendations
4.1. Assessment of cough
A thorough history is fundamental to identify the cause
of cough and should be taken for each patient with lung
cancer in order to identify the causes of cough. This
assessment should include the type of cough (produc-
tive/non-productive), trigger factors, whether cough is
nocturnal or day-time cough, its effects on quality of life
or any specific concerns patients may have (e.g. fear of
choking during a cough). This assessment should
include a careful medication review. Use of a cough
scale should be useful in identifying not only the fre-
quency of cough but also its severity and distress. A
visual analogue scale is recommended, until validated
scales specific for cancer patients are available, which
also could be used to assess the effectiveness and
responsiveness of initiated interventions. Many of the
lung cancer patients have comorbidities with other
respiratory diseases (e.g. chronic obstructive pulmonary
disease-COPD) and cough may be the result of the
underlying respiratory pathology rather than the cancer.
The timing of the start of cough is important; any
change in cough since the diagnosis with cancer or any
new cough is likely to be related with the cancer
whereas more chronic cough may be related to underly-
ing respiratory comorbidity. Iatrogenic causes of cough
should also be considered, such as radiotherapy and cer-
tain medication (e.g. ‘lone cough’ from Gefitinib, Trastu-
zumab, Methotrexate, Busulphan, Bleomycin,
antihypertensive drugs or ACE inhibitors). Lung cancer
patients may not need new investigations, as they may
already have x-rays or CT scans that can provide ade-
quate information regarding the cancer-related causes of
cough. It may, however, be necessary to carry out such
investigations if the causes of cancer-related cough are
not apparent from a detailed history.
4.2. Treating reversible causes of cough/specific
pathology
The therapeutic overall goal should first be to treat
reversible causes or specific pathology. If the patient has
an identified underlying pathology potentially causing
cough, he/she should be treated as per available guide-
lines (ie. BTS guidelines). In cough due to airway dis-
eases such as COPD or asthma, treatments directed at
the underlying condition should be used. This could be
achieved with the use of inhaled bronchodilators and
corticosteroids; for example, salbutamol has little effect
in non-asthmatic cough but may be useful when
bronchoconstriction is present. The same principle
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nergics (e.g. Hyoscine) may be particularly important in
the end of life, where the aim is to suppress secretions
and subsequent cough. Oral corticosteroids (e.g. Predni-
solone 30 mg once daily for 14 days) may also provide
rapid relief of cough due to airway inflammation either
as a direct result of tumour involvement or associated
asthmatic/eosinophilic inflammation. With cough
thought to be originating from gastro-oesophageal
reflux, PPIs and H2-receptor antagonists may be tried.
However, increasing evidence suggests that non-acid
reflux (pH 4-7) may be associated with chronic cough-
ing in some individuals. Metoclopramide and Domperi-
done are frequently used to promote GI motility and
they should be considered in selected patients where
non-acid reflux is suspected. The BTS guidelines [7]
recommend that patients with cough receiving an ACE
inhibitor should discontinu ei t .E v e ni np a t i e n t sw h e r e
ACE inhibitor treatment pre-dates coughing, their sensi-
tizing effect on the cough reflex is likely to worsen
symptoms. Also, the BTS guidelines recommend that in
prominent upper airway pathology, a trial of a topical
corticosteroid is appropriate. Productive cough may
indicate bronchiectasis, sinusitis or a lower respiratory
tract infection, and the use of antibiotics may be
appropriate.
Systemic chemotherapy, were indicated, can improve
symptoms in lung cancer, and there are a number of
studies with varied chemotherapy regimens, where
symptoms and quality of life were secondary outcomes,
showing improvements in symptoms including cough [i.
e. [26-30]]. Rapid palliation of cough (and other thoracic
symptoms) can particularly be achieved in small cell
lung cancer. Furthermore, a Cochrane review has pro-
vided evidence that external beam radiation therapy of
one or two fractions produces significant improvements
in thoracic symptoms [31]. Hence, systemic chemother-
apy and/or radiotherapy are cornerstones for symptom
management in lung cancer and the use of brachyther-
apy should also be considered as shown in our
Cochrane review.
4.3. Symptomatic management
Symptomatic treatment should start with demulcents
such as Glycerol-based ones (2 positive trials of moder-
ate quality for Glycerol [32,33]) and Simple Linctus. A
2-week course of steroids could be considered in
patients with extrinsic airway compression, although
this may not be appropriate for all patients. Centrally-
acting opioids should be the next step primarily with
Codeine linctus. While the evidence for Codeine derives
from COPD trials, opioids most likely act on the central
nervous system and their action may be the same
regardless of aetiology. Morphine and Methadone could
also be considered in patients failing to respond with
the weak opioids before introducing peripherally-acting
agents such as Levodropropizine, Moguisteine or Levo-
cloperastine where available (see review of peripherally-
acting antitussives by Dicpinigaitis [34]). Low dose of
sustained release Morphine (ie. 5 mg and sometime
10 mg twice daily) may produce adequate relief of
cough, but unlike pain, it seems that higher doses do
not necessarily improve effectiveness in relation to
cough. Constipation can be a distressing side effect for
patients, and it should be a clinical consideration when
opioids are prescribed. Agents with local anaesthetic
properties could also be considered, such as Nebulised
Lidocaine and Benzonatate (where available). The sug-
gested dose of the above agents is presented in Table 2.
Failing all these, there are a number of more experimen-
tal options that could be considered (with minimal evi-
dence and significant toxicity/side effects), such as
Baclofen, Thalidomide, Gabapentin, Carbamazepine or
Amitriptyline. Figure 1 presents the steps that are
recommended to be followed in the management of
cough in lung cancer. Due to the distressing nature of
cough in lung cancer patients, high level of symptom
burden and poor survival, methods used need to provide
Table 2 Recommended dosages for antitussives,
demulcents and topical anaesthetics
Medication Dosage
Simple linctus 5 ml tds/qds
Dextromethorphan 10-15 mg tds/qds
Codeine 30-60 mg qds
Pholcodine 10 ml tds
Morphine
(oramorph)
5 mg (single dose trial of oramorph; if effective
5-10 mg slow release morphine bd)
Diamorphine 5-10 mg CSCI/24 hrs
Methadone linctus Single dose 2 mg (2 mL of 1 mg/mL solution)
Dihydrocodeine* 10 mg tds
Hydrocodone 5 mg bd
Inhaled
cromoglycate
10 mg qds
Levodropropizine* 75 mg tds
Moguisteine* 100-200 mg tds
Levocloperastine* 20 mg tds
Nebulised
Lidocaine#
5 ml of 0.2% tds
Nebulised
Bupivacaine#
5 ml of 0.25% tds
Benzonatate* 100-200 mg qds
Prednisolone 30 mg daily for 2 weeks
t.d.s.: 3 times daily; q.d.s.: 4 times daily; csci: subcutaneously; b.d.: twice daily.
*Not available in the UK and some other countries.
#Avoid food/drinks for at least 1 hr; first dose as inpatient in case of reflex
bronchospasm.
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long-term treatment approaches should be avoided.
Initial cough management should focus on peripher-
ally acting and intermittent treatment (i.e demulcents);
more resistant symptoms require the addition of (or
replacement by) centrally acting and continuous treat-
ment. It is noted, however, that peripheral mechanisms
may be different in cancer-ulcerated mucosa in localized
cancer may result in more or less sensitivity to periph-
eral agents such as lidocaine or steroids. Furthermore,
many patients with advanced cancer will be already
receiving strong opioids for pain management which
may mean that centrally acting approaches are maxi-
mized and less well established treatments should be
explored. Behavioural interventions, such as speech
pathology training [35] and vocal hygiene may have an
adjunctive role in the management of cough in lung
cancer, but as many related techniques are based in
cough suppression they may not be all appropriate for
lung cancer patients. Examples of related techniques
include pursed lip breathing/relaxed throat breathing/
valsalva swallow/replacing cough with swallowing/dis-
traction, although none of these techniques have been
tested in cancer patients and their use is based on
experience and limited research from the wider respira-
tory illness field. Inhalations of menthol may also be
suggested, based on the premises that menthol can
reduce cough reflex sensitivity (via the TRPM8 channel)
[36], although no research with patients experiencing a
respiratory illness could be identified.
A combination of cancer-specific treatments and
symptomatic control approaches is likely to be necessary
in all patients. The specific balance of these treatments
should be determined by the individual patient’s needs
and a logical stepwise approach to seeking reversible
causes and introducing treatments.
Level of evidence
With the exception of chemoradiotherapy and some
treatments for respiratory diseases, the recommenda-
tions in the cough management pyramid of Figure 1 are
based on low level of evidence (level III-non analytic
studies-and IV-expert opinion). The grade of recom-
mendation is D or GPP (good practice). In terms of
level of confidence in the available data, the higher the
pyramid level in Figure 1 the lower the confidence level.
Conclusion
Cough is a symptom that has received little attention in
cancer supportive care research and it is frequently
undertreated in practice as there is a dearth of good
quality evidence on which clinicians can base their treat-
ment decisions. These guidelines provide an attempt to
rationalize the available evidence and offer a sensible
and practical way of managing cough in lung cancer
patients. There is an urgent need for more high quality
research in the management of cough. Also, as tradi-
tional antitussives and other cough suppressants have
variable effectiveness and significant side effects, more
novel cough treatments need to be developed in the
future based on improved understanding of pathophy-
siological causes of cough in patients with cancer.
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